KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsR&D In ProcessReceivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Eli Lilly (LLY) Shares Outstanding (2016 - 2026)

Eli Lilly filings provide 18 years of Shares Outstanding readings, the most recent being $943.5 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding changed 0.49% to $943.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $943.5 million, a 0.49% change, with the full-year FY2025 number at $944.8 million, changed 0.33% from a year prior.
  • Shares Outstanding hit $943.5 million in Q1 2026 for Eli Lilly, roughly flat from $944.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $950.8 million in Q2 2024 to a low of $943.5 million in Q1 2026.
  • Median Shares Outstanding over the past 5 years was $949.7 million (2023), compared with a mean of $948.9 million.
  • Biggest five-year swings in Shares Outstanding: dropped 0.93% in 2022 and later grew 0.12% in 2024.
  • Eli Lilly's Shares Outstanding stood at $950.6 million in 2022, then dropped by 0.08% to $949.8 million in 2023, then dropped by 0.2% to $947.9 million in 2024, then decreased by 0.33% to $944.8 million in 2025, then fell by 0.14% to $943.5 million in 2026.
  • The last three reported values for Shares Outstanding were $943.5 million (Q1 2026), $944.8 million (Q4 2025), and $946.2 million (Q3 2025) per Business Quant data.